All In MedTech

Device Trial Radar · NCT03611504

Hemospray in Gastrointestinal Bleeding: A Real-life Multicenter Cohort

Hemospray Effectiveness and Predictors of Rebleeding in Patients With Gastrointestinal Hemorrhage: A Real-life Multicenter Cohort.

Last checked: Nov 20, 2026Latest source record: Feb 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

261

Actual

Start

Jul 1, 2018

Primary completion

Dec 30, 2018

Study completion Dec 30, 2018

Sponsor

Lead sponsor
Hospital Universitario Ramon y CajalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Salamanca; Hospital del Mar; Puerta de Hierro University Hospital; Complejo Hospitalario de Navarra; Hospital de Henares; Fundación de Investigación Biomédica - Hospital Universitario de La Princesa; Quirón Madrid University Hospital; Hospital de Cruces; Hospital General Universitario Gregorio Marañon; Hospital Universitario Central de Asturias; Hospital Universitario de Cabuenes; Hospital Universitario Doctor Peset; Hospital del Rio Hortega; Hospital Universitario Madrid Sanchinarro; Hospital de Aviles; Hospital IMQ Zorrozaurre
First posted
Aug 2, 2018

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an observational, retrospective, analytical, and multicenter study conducted at 17 hospitals. Our research aims to assess the effectiveness of Hemospray® in patients with gastrointestinal bleeding in clinical practice. Besides, we aim to detect predictors of treatment failure defined as unsuccessful immediate hemostasis or rebleeding.

Conditions

  • Gastrointestinal Hemorrhage
  • Ulcer Hemorrhage
  • Tumor Bleeding

Interventions

  • Hemospray®Device

    Hemospray® application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hemospray® intraprocedural bleeding controlTime frame: From Hemospray® first application up to the end of the endoscopic procedure. This variable should be assessed in day 1.
  2. Rebleeding rateTime frame: Date of Hemospray® application until rebleeding, assessed up to 48 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.